AVIEW LCS vs Merge PACS
AI Verdict
Choose AVIEW LCS if…
Choose AVIEW LCS if your primary need is a highly specialized AI-powered solution for comprehensive lung cancer screening and cardiopulmonary assessment. This tool excels in automated detection and analysis of lung nodules, emphysema, and coronary artery calcification from low-dose CT scans, providing detailed quantification and Lung-RADS classification to enhance diagnostic accuracy in pulmonology and cardiology workflows.
View AVIEW LCS →Choose Merge PACS if…
Choose Merge PACS if you require an enterprise-level Picture Archiving and Communication System to streamline radiology workflows across a multi-site health system. This platform is ideal for consolidating imaging data from various modalities, integrating diverse third-party AI applications through a single worklist, and providing robust image management with flexible deployment options to support complex diagnostic environments.
View Merge PACS →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AVIEW LCS | Merge PACS |
|---|---|---|
| Pricing | Contact for pricing | Contact vendor |
| Deployment | Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker) | On-premise, Cloud, Hybrid |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Merge PACSMerge PACS prioritizes overall workflow efficiency and a unified user experience across multiple modalities with features like a customizable worklist and enhanced diagnostic workflows. While AVIEW LCS offers significant automation for specific tasks, Merge PACS's broader focus on streamlining the entire diagnostic process for diverse cases gives it an edge in enterprise-wide usability.
Clinical Value
AVIEW LCSAVIEW LCS offers direct, quantifiable clinical value through its AI-powered detection and analysis of lung nodules, COPD, and coronary artery calcification from a single CT scan, demonstrably enhancing diagnostic accuracy and reducing radiologist workload. Merge PACS, while crucial for imaging workflows, primarily serves as a platform for diagnostic interpretation and AI integration, rather than providing direct AI-driven diagnostic insights itself.
Pricing & Value
TieBoth AVIEW LCS and Merge PACS require direct contact with their respective vendors for pricing information, indicating a lack of public transparency. Without specific pricing details or comprehensive return on investment (ROI) studies for either product, it is not possible to definitively determine which offers superior value.
Enterprise Readiness
Merge PACSMerge PACS is explicitly designed as an 'enterprise-level Picture Archiving and Communication System' for multi-site health systems, offering comprehensive image management and broad integration with EMR/EHR, RIS, HIS, and VNA systems [JSON]. While AVIEW LCS provides flexible deployment and PACS/RIS integration, Merge PACS offers a more robust and foundational infrastructure for enterprise imaging needs [JSON, 2, 6].
Innovation
AVIEW LCSAVIEW LCS demonstrates greater innovation in its direct application of advanced deep learning AI for multi-disease detection and quantitative analysis from a single low-dose CT scan, offering novel diagnostic capabilities and significantly reducing radiologist workload. Merge PACS's innovation lies more in its platform approach to integrating various AI tools and providing a flexible, cloud-ready enterprise imaging solution, which is a different aspect of innovation.
Support & Docs
Merge PACSMerge PACS, as an established enterprise PACS, provides a range of technical documentation including DICOM Conformance Statements and explicitly mentions 'Product support' on its website. While AVIEW LCS also has support documentation, the broader and more detailed technical resources available for Merge PACS suggest a more comprehensive and established support infrastructure for an enterprise-grade product.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AVIEW LCS | Merge PACS |
|---|---|---|
| Name | AVIEW LCS | Merge PACS |
| Company | Coreline Soft Co. | Merative |
| Primary Focus | AI-powered solution for the detection and analysis of lung nodules, COPD, and coronary artery calcification from a single low-dose CT scan. | Enterprise-level Picture Archiving and Communication System (PACS) that streamlines radiology workflows, consolidates imaging data, and integrates AI insights across multi-site health systems. |
| Key AI Capabilities | Automated lung nodule detection and analysis, Lung-RADS classification and reporting, Nodule volume quantification and 3D segmentation, Emphysema quantification (LAA index), Coronary Artery Calcification (CAC) scoring (Agatston, volume, mass), Automated comparison of nodules in follow-up CT scans. | AI integration and readiness (single worklist access to 3rd party AI applications) |
| Specialties | Cardiology, Oncology, Pulmonology, Radiology | Cardiology, Radiology |
| Integration with other systems | Integration with PACS/RIS and third-party platforms | Integration with EMR/EHR, RIS, HIS, and VNA systems |
Videos
Demos, reviews, and walkthroughs featuring AVIEW LCS and Merge PACS.